About Leucine-rich repeat protein 1
Leucine-rich repeat protein 1 (LRR1) is a protein
from Homo sapiens identified by UniProt accession
Q96L50, 414 residues long.
MolForge cross-references it against 0 known binders and
90 disease associations.
Target properties
| Protein name | Leucine-rich repeat protein 1 |
| UniProt accession | Q96L50 |
| Gene | LRR1 |
| Organism | Homo sapiens |
| Length | 414 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (90)
Diseases linked to this target (Open Targets).
- mathematical ability · score 0.26
- neurodegenerative disease · score 0.20
- self reported educational attainment · score 0.18
- blood protein measurement · score 0.18
- esophageal squamous cell carcinoma · score 0.15
- neuroblastoma · score 0.15
- Ewing sarcoma · score 0.15
- C-reactive protein measurement · score 0.14
- fatty acid measurement · score 0.14
- eicosadienoic acid measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96L50-F1 | alphafold | PREDICTED | 88.20 | — |
Amino-acid sequence (414 residues)
MKLHCEVEVI SRHLPALGLR NRGKGVRAVL SLCQQTSRSQ PPVRAFLLIS TLKDKRGTRY ELRENIEQFF TKFVDEGKAT VRLKEPPVDI CLSKAISSSL KGFLSAMRLA HRGCNVDTPV STLTPVKTSE FENFKTKMVI TSKKDYPLSK NFPYSLEHLQ TSYCGLVRVD MRMLCLKSLR KLDLSHNHIK KLPATIGDLI HLQELNLNDN HLESFSVALC HSTLQKSLRS LDLSKNKIKA LPVQFCQLQE LKNLKLDDNE LIQFPCKIGQ LINLRFLSAA RNKLPFLPSE FRNLSLEYLD LFGNTFEQPK VLPVIKLQAP LTLLESSART ILHNRIPYGS HIIPFHLCQD LDTAKICVCG RFCLNSFIQG TTTMNLHSVA HTVVLVDNLG GTEAPIISYF CSLGCYVNSS DMLK
Explore Leucine-rich repeat protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets